Medicinova Stock Alpha and Beta Analysis

MNOV Stock  USD 2.38  0.31  14.98%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as MediciNova. It also helps investors analyze the systematic and unsystematic risks associated with investing in MediciNova over a specified time horizon. Remember, high MediciNova's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to MediciNova's market risk premium analysis include:
Beta
(2.36)
Alpha
1.21
Risk
8.04
Sharpe Ratio
0.0781
Expected Return
0.63
Please note that although MediciNova alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, MediciNova did 1.21  better than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of MediciNova stock's relative risk over its benchmark. MediciNova has a beta of 2.36  . As returns on the market increase, returns on owning MediciNova are expected to decrease by larger amounts. On the other hand, during market turmoil, MediciNova is expected to outperform it. At this time, MediciNova's Price Book Value Ratio is fairly stable compared to the past year. Price Fair Value is likely to climb to 1.63 in 2024, whereas Tangible Book Value Per Share is likely to drop 0.93 in 2024.

Enterprise Value

82.81 Million

Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out MediciNova Backtesting, MediciNova Valuation, MediciNova Correlation, MediciNova Hype Analysis, MediciNova Volatility, MediciNova History and analyze MediciNova Performance.
For more information on how to buy MediciNova Stock please use our How to Invest in MediciNova guide.

MediciNova Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. MediciNova market risk premium is the additional return an investor will receive from holding MediciNova long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in MediciNova. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate MediciNova's performance over market.
α1.21   β-2.36

MediciNova expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of MediciNova's Buy-and-hold return. Our buy-and-hold chart shows how MediciNova performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

MediciNova Market Price Analysis

Market price analysis indicators help investors to evaluate how MediciNova stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading MediciNova shares will generate the highest return on investment. By understating and applying MediciNova stock market price indicators, traders can identify MediciNova position entry and exit signals to maximize returns.

MediciNova Return and Market Media

The median price of MediciNova for the period between Tue, Sep 3, 2024 and Mon, Dec 2, 2024 is 1.83 with a coefficient of variation of 10.43. The daily time series for the period is distributed with a sample standard deviation of 0.19, arithmetic mean of 1.83, and mean deviation of 0.15. The Stock received substential amount of media coverage during this period.
 Price Growth (%)  
       Timeline  
1
StockNews.com Initiates Coverage on MediciNova - MarketBeat
09/11/2024
2
MNOV MN-166 to be Evaluated in NIH-Sponsored Expanded Access Trial in ALS
09/30/2024
3
Acquisition by Nagao Hideki of 20000 shares of MediciNova at 1.34 subject to Rule 16b-3
10/04/2024
4
MediciNova NASDAQMNOV shareholders incur further losses as stock declines 11 percent this week, taking five-year losses to 80
11/07/2024
5
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office forNew Patent Covering MN-001 for Triglyceride Synthesis in the Liver
11/14/2024
6
Acquisition by Beaver Carolyn of 15000 shares of MediciNova at 5.4 subject to Rule 16b-3
11/21/2024
7
MNOV Monetary Damages Due Following SanofiNovartis Patent Dispute Settlement
11/25/2024

About MediciNova Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including MediciNova or other stocks. Alpha measures the amount that position in MediciNova has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
 2023 2024 (projected)
Days Sales Outstanding328.79292.26
PTB Ratio1.181.63

MediciNova Upcoming Company Events

As portrayed in its financial statements, the presentation of MediciNova's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, MediciNova's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of MediciNova's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of MediciNova. Please utilize our Beneish M Score to check the likelihood of MediciNova's management manipulating its earnings.
15th of February 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
15th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Build Portfolio with MediciNova

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Additional Tools for MediciNova Stock Analysis

When running MediciNova's price analysis, check to measure MediciNova's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MediciNova is operating at the current time. Most of MediciNova's value examination focuses on studying past and present price action to predict the probability of MediciNova's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MediciNova's price. Additionally, you may evaluate how the addition of MediciNova to your portfolios can decrease your overall portfolio volatility.